Phase 3 Trial of Epicutaneous Immunotherapy
... in Toddlers with Peanut Allergy
Recent publication
The efficacy and safety of immunotherapy for peanut allergy in one to three year old children was tested in a double-blind, placebo-controlled, randomized multicenter phase 3 trail over 12 months. Children received immunotherapy with a peanut protein-containing patch or placebo.
The results were published in the New England Journal of Medicine. Study authors include Prim. Assoc. Prof. PD Dr. Thomas Eiwegger, head of the Clinical Department of Pediatrics and Adolescent Medicine at St. Pölten University Hospital.
Greenhawt M, Sindher SB, Wang J, O’sullivan M, Du toit G, Kim EH et al. Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy. New England Journal of Medicine. 2023 May 11;388(19):1755-1766. doi: 10.1056/NEJMoa2212895
Prim. Assoc. Prof. Univ.-Doz. Dr. Thomas Eiwegger
Scientific Working Group Clinical Immunology, Division of Paediatrics (University Hospital St. Pölten)
